西藏东财中证沪港深创新药产业交易型开放式指数证券投 资基金 基金管理人:西藏东财基金管理有限公司 基金托管人:广发证券股份有限公司 报告送出日期:2025年07月19日 §1 重要提示 基金管理人的董事会及董事保证本报告所载资料不存在虚假记载、误导性陈述或 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 基金托管人广发证券股份有限公司根据本基金基金合同规定，于2025年07月16日 复核了本报告中的财务指标、净值表现和投资组合报告等内容，保证复核内容不存在 虚假记载、误导性陈述或者重大遗漏。 基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基 金一定盈利。 基金的过往业绩并不代表其未来表现。投资有风险，投资者在作出投资决策前应 仔细阅读本基金的招募说明书。 本报告中财务资料未经审计。 本报告期自2025年04月01日起至2025年06月30日止。 | §2 | 基金产品概况 | | --- | --- | | 基金简称 | 创新药ETF沪港深 | | 场内简称 | 创新药ETF沪港深 | | 基金主代码 | 159622 | | 基金运作方式 | 契约型开放式 | | 基 ...

ETF Industry News - The three major indices experienced fluctuations and declines, with the Shanghai Composite Index down by 0.22%, the Shenzhen Component Index down by 0.48%, and the ChiNext Index down by 0.66%. Several computer sector ETFs saw increases, including the Cloud 50 ETF (560660.SH) which rose by 1.64% and the Cloud Computing Hong Kong-Shenzhen ETF (517390.SH) which increased by 1.05%. Conversely, multiple pharmaceutical and biotechnology ETFs declined, with the Tianhong Innovative Drug ETF (517380.SH) down by 2.11% and the Hong Kong-Shenzhen Innovative Drug ETF (159622.SZ) down by 2.03% [1][2]. - The total scale of stock ETFs has returned to over 3 trillion yuan, with the number of stock ETFs reaching 975 and a total net asset value of approximately 3.05 trillion yuan, accounting for 70.76% of the entire ETF market [1][2]. Market Overview - On June 26, the three major indices collectively fell, with the Shanghai Composite Index closing at 3448.45 points, the Shenzhen Component Index at 10343.48 points, and the ChiNext Index at 2114.43 points. The highest intraday points were 3462.75, 10440.73, and 2142.21 respectively. The Nikkei 225, CSI 300, and CSI A500 ranked higher in performance, with daily changes of 1.65%, -0.35%, and -0.36% respectively [3]. Sector Performance - In the performance of various sectors, banking, telecommunications, and defense industries ranked higher with daily increases of 1.01%, 0.77%, and 0.55% respectively. In contrast, the automotive, non-bank financial, and pharmaceutical sectors lagged behind with declines of -1.37%, -1.2%, and -1.05% respectively. Over the past five trading days, non-bank financial, computer, and defense industries showed strong performance with increases of 7.69%, 6.15%, and 4.75% respectively [6]. ETF Market Performance - The overall performance of ETFs was analyzed based on their scale and daily changes. Commodity ETFs performed the best with an average increase of 0.11%, while cross-border ETFs had the worst performance with an average decrease of -0.72% [8]. - The top five performing ETFs today included the Communication Equipment ETF (159583.SZ), Cloud 50 ETF (560660.SH), and Gold Stock ETF (159322.SZ), with returns of 1.83%, 1.64%, and 1.44% respectively [10]. Trading Volume of Different ETF Categories - The trading volume of various ETF categories was reported, with the top three stock ETFs by trading volume being the CSI 300 ETF (510300.SH) at 3.746 billion yuan, A500 ETF (512050.SH) at 3.740 billion yuan, and A500 ETF by Harvest (159351.SZ) at 3.324 billion yuan [12].

早盘提示 | 板块 | 品种 | 多（空） | 推荐理由 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 【行情复盘】 | | | | | | | | | 周四市场在等待中美框架协议的细节内容正式公布，两市主要指数窄幅整理。两市 | | | | | | | | | 成交额 1.27 万亿元，变化不大。中证 1000 指数收 6192 点，涨 5 点，涨幅 0.09%； | | | | | | | | | 中证 500 指数收 5799 点，涨 6 点，涨幅 0.12%；沪深 300 指数收 3892 点，跌 2 点， | | | | | | | | | 跌幅-0.06%；上证 50 指数收 2691 点，跌 1 点，跌幅-0.03%。行业与主题 ETF 中涨 | | | | | | | | | 幅居前的是创新药 ETF 沪港深、黄金股 ETF、科创医药指数 ETF、创新药 ETF、科创 | | | | | | | | | 指数中涨幅居前的是影视院线、贵金属、生物制品、通信设备、化学制药指数，跌 | | | | | | | ...

ETF Industry News - The three major indices experienced fluctuations and declines, with the Shanghai Composite Index down by 0.18%, the Shenzhen Component Index down by 0.61%, and the ChiNext Index down by 0.68. However, several ETFs in the pharmaceutical and biotechnology sector saw gains, including the Huatai-PB Innovation Drug ETF (517120.SH) up by 1.96%, the Innovation Drug ETF for Shanghai-Hong Kong-Shenzhen (517110.SH) up by 1.86%, and the Innovation Drug ETF for Hong Kong-Shenzhen (159622.SZ) up by 1.80% [1][4][11] - According to Everbright Securities, multiple domestic innovative drug research projects have been selected for the 2025 ASCO conference, indicating a robust trend in domestic pharmaceutical research, particularly in cancer treatment [1][4] - Minsheng Securities highlighted that the innovative drug sector is a key focus for the year, emphasizing areas such as anti-tumor, autoimmune, GLP-1, stem cell, and gene therapy, while also monitoring domestic innovation in pharmaceuticals and medical consumption, especially in the beauty sector [1][4] ETF Market Performance - As of April 2025, the total scale of ETFs in the Shanghai and Shenzhen markets exceeded 4 trillion yuan, with the Shanghai market having 680 ETFs valued at 29,625.45 billion yuan and the Shenzhen market having 467 ETFs valued at 10,947.55 billion yuan [3] - The cross-border ETFs performed the best today, with an average increase of 0.60%, while commodity ETFs had the worst performance, with an average decrease of 0.67% [9] - The top-performing ETFs today included the Huatai-PB Innovation Drug ETF (517120.SH), the Innovation Drug ETF for Shanghai-Hong Kong-Shenzhen (517110.SH), and the Innovation Drug ETF for Hong Kong-Shenzhen (159622.SZ), with respective gains of 1.96%, 1.86%, and 1.80% [11][12] Trading Volume - The top three ETFs by trading volume today were the A500 ETF (512050.SH) with 2.714 billion yuan, the A500 Index ETF (159351.SZ) with 2.466 billion yuan, and the CSI 300 ETF (510300.SH) with 2.285 billion yuan [14][15]